Eli Lilly and Company
LLY
$754.53
$3.080.41%
NYSE
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 49.00B | 45.04B | 40.86B | 38.92B | 35.93B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.00B | 45.04B | 40.86B | 38.92B | 35.93B |
| Cost of Revenue | 8.97B | 8.42B | 7.80B | 7.49B | 7.13B |
| Gross Profit | 40.03B | 36.62B | 33.06B | 31.43B | 28.80B |
| SG&A Expenses | 8.66B | 8.13B | 7.63B | 7.34B | 7.14B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 28.83B | 27.54B | 25.97B | 25.03B | 24.12B |
| Operating Income | 20.17B | 17.50B | 14.90B | 13.89B | 11.81B |
| Income Before Tax | 13.60B | 12.68B | 10.15B | 8.99B | 7.56B |
| Income Tax Expenses | 2.49B | 2.09B | 1.78B | 1.65B | 1.42B |
| Earnings from Continuing Operations | 11.11K | 10.59K | 8.37K | 7.34K | 6.14K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 11.11B | 10.59B | 8.37B | 7.34B | 6.14B |
| EBIT | 20.17B | 17.50B | 14.90B | 13.89B | 11.81B |
| EBITDA | 22.00B | 19.27B | 16.57B | 15.50B | 13.37B |
| EPS Basic | 12.32 | 11.74 | 9.28 | 8.14 | 6.81 |
| Normalized Basic EPS | 13.49 | 11.69 | 9.95 | 9.32 | 7.92 |
| EPS Diluted | 12.29 | 11.71 | 9.25 | 8.12 | 6.79 |
| Normalized Diluted EPS | 13.46 | 11.66 | 9.92 | 9.30 | 7.91 |
| Average Basic Shares Outstanding | 3.60B | 3.61B | 3.61B | 3.61B | 3.60B |
| Average Diluted Shares Outstanding | 3.61B | 3.62B | 3.62B | 3.61B | 3.61B |
| Dividend Per Share | 5.40 | 5.20 | 5.03 | 4.86 | 4.69 |
| Payout Ratio | 43.74% | 44.20% | 54.12% | 59.60% | 68.77% |